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Abstract 
Small heat-shock proteins (sHsps) are a diverse family of intra-cellular molecular chaperone proteins that 
play a critical role in mitigating and preventing protein aggregation under stress conditions such as 
elevated temperature, oxidation and infection. In doing so, they assist in the maintenance of protein 
homeostasis (proteostasis) thereby avoiding the deleterious effects that result from loss of protein 
function and/or protein aggregation. The chaperone properties of sHsps are therefore employed 
extensively in many tissues to prevent the development of diseases associated with protein aggregation. 
Significant progress has been made of late in understanding the structure and chaperone mechanism of 
sHsps. In this review, we discuss some of these advances, with a focus on mammalian sHsp hetero-
oligomerisation, the mechanism by which sHsps act as molecular chaperones to prevent both amorphous 
and fibrillar protein aggregation, and the role of post-translational modifications in sHsp chaperone 
function, particularly in the context of disease. 
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Abstract (word count = 159) 
Small heat-shock proteins (sHsps) are a diverse family of intracellular molecular chaperone proteins that play a 
critical role in preventing protein unfolding, misfolding and aggregation, particularly under stress conditions 
such as elevated temperature, oxidation and infection. In doing so, they assist in the maintenance of protein 
homeostasis (proteostasis) and thereby avoid the deleterious effects that result from loss of protein function 
and/or protein aggregation. The chaperone properties of sHsps are therefore employed extensively in many 
tissues to prevent the development of diseases associated with protein aggregation. There has been much 
research into the structure and mechanism of chaperone action of sHsps over approximately the past 30 years, 
and significant progress has been made of late, however, there are still many unanswered questions relating to 
these aspects of sHsps. In this review, we outline some of the recent advances in understanding the structure and 







































































The proteome is inherently meta-stable [1,2]. Arguably, the most important means nature uses to maintain the 
integrity of the proteome (i.e. proteostasis) is via network of molecular chaperone proteins, which are present 
both intra- and extracellularly. The abundant and ubiquitous small heat-shock proteins (sHsps) are a family of 
intracellular molecular chaperones that interact with unfolding target proteins to stabilise them and prevent their 
aggregation and precipitation. They do so under constitutive conditions but are particularly prevalent under 
stress conditions when their expression is significantly up-regulated. Many sHsps have a wide tissue distribution 
and as a result are associated with a plethora of disease states, particularly those related to compromised 
proteostasis (e.g. involving defective protein folding).  In the eye lens, for example, the high concentration of 
the two major sHsps, A- and B-crystallin, prevents protein aggregation, in addition to ensuring proper lens 
transparency. In this review, we summarise recent research into sHsp structure, function and interactions. 
Following a brief introduction to the structure and chaperone action of sHsps and the effects of sHsp post-
translational modification, specifically phosphorylation, we discuss the involvement of sHsps in diseases, 
particularly neurodegenerative ones. Related to this, we examine the effect of sHsp mutations on chaperone 
function and hence disease manifestation, particularly cataract.  
 
SECTION I: The structure and function of sHsps 
Each sHsp is comprised of three regions: N- and C-terminal regions which are separated by a highly conserved 
-crystallin domain (ACD) of approximately 80 amino acids in length that is a defining characteristic of all 
sHsps.  By contrast, the N- and C-terminal flanking regions are variable in length between the sHsps and lack 
significant sequence similarity. The structures of mammalian sHsps have proved difficult to decipher. Of late, a 
battery of powerful and complementary techniques, i.e. X-ray crystallography, solid-state and solution NMR 
spectroscopy, small-angle X-ray scattering (SAXS), mass spectrometry and cryo- and transmission electron 
microscopy (cryo-EM and TEM, respectively) have been utilised to gain unprecedented insight into the structure 
of sHsps. We shall only discuss the salient structural features that have become apparent from these studies as 
more in-depth discussion has been presented in recent reviews of sHsp structure [3-5].  
 
The subunit monomeric mass of sHsps ranges from 15 to 40 kDa, however their classification (and 




































































species in solution. In the case of Bc, these oligomers are highly heterogeneous with a mass range under 
physiological conditions, as determined by light scattering, of 420 – 980 kDa [6] and an average mass of 
approximately 650 kDa [7]. Moreover, sHsps are highly dynamic species with extensive subunit exchange 
occurring which may be important in their chaperone function [8].  In addition, the dynamic nature of sHsps is 
also due to large portions, particularly within the N- and C-terminal regions, having little well-defined 
secondary structure and exhibiting flexibility. The extreme C-terminus is very much so with solution-phase 
NMR spectroscopy revealing that the last 10 and 12 amino acids in Ac and Bc respectively are unstructured 
C-terminal extensions that have mobility comparable to isolated peptides of the same length [9-12]. This 
heterogeneity, dynamism and flexibility have inhibited crystallisation attempts of the full-length proteins, 
however X-ray crystal structures are available for some non-mammalian sHsps which lack the flexible C-
terminal extensions and form well-ordered oligomers, e.g. of Hsp16.5, a 24-mer from a hyperthermophilic 
archeon Methanococcus jannaschii  [13] (Fig. 1A) and Hsp16.9, a 12-mer from wheat [14].  
 
More recently, crystal structures of the isolated ACD from Bc [15], Hsp27 [16] and Hsp20 [15] have 
confirmed the predicted features of this domain, i.e. that it is highly -sheet in character and arranged in an 
immunoglobulin-like fold. Structures of the ACD of Ac and Bc that also contained the majority of the C-
terminal region, but not the C-terminal extension, were recently solved [17]. These structures demonstrated that 
two -strands (numbers 6 and 7) from each monomer are arranged in an anti-parallel manner and provide the 
dimer interface that mediates higher-order assembly [17] (Fig. 1B). Furthermore, the conserved I-X-I motif 
(I159-P160-I161 in Bc) in the C-terminal region of one subunit can bind in a groove formed between the 4 
and 8 strands on a nearby subunit [18] (Fig. 1B). The I-X-I motif is the central part of a nine amino acid 
palindromic sequence that enables equivalent interactions in both directions of the polypeptide chain with other 
subunits. As a result, Bc polydisperse oligomerisation is facilitated which prevents its crystallisation. Crystal 
formation is deleterious to lens transparency and this palindromic sequence may be the crucial factor in 
inhibiting crystallisation and in enabling dynamic interactions both with itself and its target proteins during 
chaperone action. 
There is much evidence, e.g. from the above-mentioned X-ray crystallographic studies and mass spectrometry 
[19], that the building block of the sHsp oligomer is a dimer. In agreement with the X-ray crystallographic 
studies, a solution and solid-state NMR and SAXS investigation of full-length Bc concluded that the ACD 




































































N-terminal flanking region has two short helices and a small stretch of anti-parallel -sheet near the boundary 
with the ACD [21]. The heterogeneity of NMR resonances, however, implied that significant conformational 
mobility exists in the N-terminal region. From these data, in combination with TEM and SAXS measurements, a 
model for the quaternary arrangement of Bc was constructed [21]. 
 
The quaternary structure of Bc has been studied for many years, yet there is no agreement as to the precise 
quaternary arrangement of mammalian sHsp oligomers with various models proposed (summarised in [22]). 
TEM and cryo-EM studies under a variety of solution conditions and temperatures have provided insight into 
the quaternary arrangement of the Bc oligomer. Under physiological conditions, human Bc forms large 
roughly spherical assemblies of 8-18 nm in diameter [7,23]. Under partially denaturing conditions and elevated 
temperature, Bc also assembles into amyloid fibrils as revealed by TEM and atomic force microscopy [24,25]. 
Cryo-EM reconstructions applied to Bc suggest a dynamic and variable asymmetric quaternary structure, with 
a roughly spherical protein shell of average diameter ~15 nm which surrounds a large central cavity of ~8 nm in 
diameter [7,23,26]. By contrast, for particular purifications of Bc, TEM studies reveal a homogeneous 
population of defined oligomers, comprising 24 subunits [27]. The 3D reconstructions from these images show 
13.5 nm diameter sphere-like structures, with an 8.5 nm diameter cavity, and a symmetrical shell of thickness 
measuring 2.5 to 4.0 nm [27], with large openings in the shell leading to the interior [27] (Fig. 1C).  A large 
central cavity is characteristic of sHsp oligomers (Fig. 1C), as was predicted from simple consideration of 
polypeptide occupancy within such oligomers [28]. 

-Crystallin in the lens 
In humans, there are ten sHsps (HSPB1-10), the predominant being A-crystallin (Ac, HSPB4), B-crystallin 
(Bc, HSPB5) and Hsp27 (HSPB1). -Crystallin (c), the complex between Ac and Bc subunits (at a 3:1 
molar ratio of Ac to Bc in humans [29]) that is present in the eye lens, along with the other crystallins ( and 
), forms a concentrated, closely associated and ordered array that enables proper refraction of light through the 
lens and its focusing onto the retina. Cis the principal lens protein and, like its individual subunits, c forms 
large, heterogeneous, oligomeric and dynamic complexes, in this case of ~160 to 1,000 kDa in mass [19,23,30]. 
X-ray and neutron solution scattering experiments have shown that c increases in size significantly at higher 




































































65oC [33]. This change is not reversed by cooling, in contrast to the behaviour of c at high pressure where 
reversibility is observed [35]. Neutron scattering experiments of complexes formed between c and E-
crystallin at high temperature (65oC) demonstrated that the latter binds inside the central cavity of c [33] most 
likely becoming more surface-exposed at higher temperature due to major structural rearrangements (including 
partial unfolding) that occur to c at these temperatures leading to exposure of the core of the oligomer. Access 
to the core would be facilitated by the porous nature of the c oligomer [27], i.e. the presence on its surface of 
openings or ‘fenestrations’ [32].  Interestingly, under milder stress conditions, target proteins are probably 
located in the ‘fenestrations’ rather than inside the oligomer cavity [32,36] implying that c has a variety of 
modes of interaction with target proteins, depending on the stress conditions.  
 
For many years, c was regarded as simply a ‘filler’ protein that was only found in the lens in high 
concentrations to ensure proper lens transparency. This situation is certainly not true nowadays. Major research 
interest in c (and sHsps in general) was sparked by two seminal observations: (1) Bhat and Nagineni’s finding 
[37] that c is present in many non-lens tissues and (2) Horwitz’s identification of the molecular chaperone 
activity of c whereby it prevents the aggregation and precipitation of a diversity of proteins under stress 
conditions, e.g. elevated temperature [38]. Horwitz’s observation was an experimental verification of Ingolia 
and Craig’s earlier classification of c as a member of the sHsp molecular chaperone family [39]. In the lens, 
the chaperone ability of c is of paramount importance in that it prevents the aggregation and precipitation of 
the crystallin proteins and hence delays the onset of age-related cataract. In this section we will discuss the role 
of c in the lens. 
 
C possesses two interlinking characteristics within the eye lens that are crucial to maintaining lens 
transparency and hence visual accuity, namely its structural organisation and its chaperone activity. Firstly, 
however, it is helpful to describe the unusual environment of the lens to gain a further appreciation of the 
importance of c’s biological role in this tissue. The avascular eye lens, surrounded by a collagen rich capsule, 
is composed of fibre cells, which develop from the single layer of epithelial cells on the anterior surface of the 
lens [40]. The lens fibre cells undergo a differentiation process involving cell elongation, expression of the 
predominant lens proteins, the crystallins [41], and degradation of cellular organelles, including the removal of 




































































light scattering structures from the light path [43].  Lens transparency is limited by absorption and scattering of 
visible light. Visible light absorption is usually negligible for eye lenses since the electronic energy level 
separations of proteins in general, and thus including the crystallins, are too great to enable molecules to be 
promoted to the excited state upon irradiation by visible light. Lens transparency is thus determined by 
scattering of light by the lens cytoplasm protein solution [45].   
 
Crystallin protein concentration has been estimated at approximately 200 mg/mL in the outer lens cortex, and up 
to 460 mg/mL in the central lens nucleus [46,47]. Despite this extremely high protein concentration and high 
degree of organisation in the lens, the crystallin proteins do not crystallise, and are free to move [45]. The 
crystallins are organised in a highly stable supramolecular -sheet structure within the lens [48-50]. Lens 
transparency is thought to be maintained by a liquid-like, short-range order in the highly concentrated crystallin 
solutions, as found in dense liquids or glasses [51]. C comprises 30-40% w:w of the lens soluble protein 
[26,52], and is thus a key player in this highly organised structural array.  
 
The loss of cellular organelles in the lens renders the lens fibre cells incapable of protein synthesis, hence there 
is almost no protein turnover in the lens. Consequently, the crystallin proteins must be maintained in a stable 
state throughout the lifespan of the organism. The chaperone action of c in preventing the aggregation of itself 
and - and -crystallins [38,53-55] is therefore especially important in the lens given the absence of cellular 
organelles and lack of new protein production. Indeed, it has been proposed that the reason for the 
predominance of Ac over Bc in the lens is that Ac acts as a chaperone for Bc, which is intrinsically less 
stable than Ac [53,56]. 
 
Expression and function of sHsps extra-lenticularly 
Bhat [37] and Horwitz’s [38] discoveries are highly interconnected: the extensive extra-lenticular expression of 
c and other sHsps unquestionably arises from their fundamental chaperone activity, i.e. nature has utilised 
their activity in many and varied roles in cells in order to maintain proteostasis. In addition to the lens, Bc is 
also located in many parts of the body and is found at high levels in the retina, heart, skeletal muscle, skin, 
brain, spinal cord, kidneys, lungs [37,57,58], the cochleae of the mammalian ear [59], and the lacrimal gland 




































































of the lens, Bc has a wide variety of metabolic and regulatory functions [62,63]; expression is induced by 
stress, for example by pH extremes, elevated temperature, chemical or heavy metal exposure, or hypertonic 
stress [64-66] and this confers both thermotolerance [67] and protection against oxidative stress to cells [68,69]. 
 
Many of the other members of the sHsp family exhibit wide extra-lenticular tissue distribution with Hsp20, for 
example, being constitutively and highly expressed in all types of muscle [70]. Hsp22, Hsp27 and Bc are also 
present in muscle cells, along with being expressed in many other cell types including neurons [70]. The extra-
lenticular expression of the major sHsps is summarized in Table 1. 
 
Outside the lens, the sHsps play a vital role in maintaining cell viability under stress conditions: they can reach 
levels of up to 1% of the total cellular protein pool following stress and they are the most acutely induced of the 
heat-shock proteins (Hsps). Moreover, the sHsps are an integral component of the proteostasis network in cells 
and their chaperone (mal)function and/or over-expression is associated with many diseases, e.g. 
neurodegenerative diseases, various cancers, cataract, cardiomyopathies and multiple sclerosis [71,72] (see 
Section III). The significance of sHsp malfunction in the context of disease is exemplified by the development 
of therapeutics that target expression of one sHsp, Hsp27, for the treatment of bladder, prostate and pancreatic 
cancers [73]. The common theme from this work is that failure of sHsps to act, through their chaperone activity, 
to stabilise target proteins and prevent their improper interactions in cells can cause disease.  
 
Hetero-oligomerisation of sHsps 
Whilst much work has focussed on the structure and function of homo-oligomeric forms of sHsps (see 
discussion above), in vivo sHsps most likely exist predominately as hetero-oligomers. For example, both Hsp27 
and αBc are expressed in the kidneys, bladder, lungs, stomach, cardiac and skeletal muscle [66,74-76] and co-
localise in both normal and pathological tissues of neurodegenerative patients [74,77,78]. Moreover, they 
associate, to a partial degree, with each other in these tissues [79] and in stably transfected HeLa cells 
expressing wild type or the disease-causing mutant R120G Bc [80]. Mixing of subunits is facilitated by the 
dynamic subunit exchange of mammalian sHsps [8,81,82] and is proposed to play a functional role in chaperone 
action (see next section). We have recently used mass spectrometry to quantify the rate of subunit exchange 
from Hsp27 and αBc homo-oligomers to form hetero-oligomers, and characterise the end products [83]. The rate 




































































and Bc [81,83]. The hetero-oligomers had masses and thermo-stabilities intermediate of the homo-oligomers 
and their chaperone ability was equivalent to that of αBc (and better than Hsp27).  
 
To-date, there is also evidence for the formation of hetero-oligomeric complexes between αA- and αBc [37,54], 
αAc and Hsp27 [81], HspB2 and HspB3 [84,85], αBc and Hsp20 [86] and Hsp27 and Hsp20 [82]. However, 
caution is required in interpreting work that has involved adding a bulky tag directly to the sHsps to measure 
sub-unit exchange (e.g. adding green fluorescent protein or one of its derivatives for fluorescence energy 
transfer studies) as these can directly interfere with the dynamism of the sHsps, their ability to form oligomers 
and thus their chaperone function [87,88]. The formation of hetero-oligomers between sHsps is temperature 
dependent [8,81,82,89] and, upon heat shock, the hetero-oligomeric assemblies of Hsp27 and αBc in cells 
dissociate and reform once the cell has recovered [79]. This raises questions as to whether homo- and hetero-
oligomeric forms of sHsps play different functional roles in the cells. For example, variation in the subunit 
composition of hetero-oligomers (as opposed to homo-oligomers) may influence the interaction with and 
binding of target proteins and therefore facilitate interactions with some cellular components in preference to 
others.  
 
The chaperone mechanism of sHsps 
The sHsps are typically classified as ‘holdase’ chaperones, however, this description does not fully describe the 
multi-faceted nature by which they can interact with target proteins to prevent their aggregation. Whilst the 
sHsps can bind tightly to, and form high-molecular-mass complexes with, destabilised protein intermediates to 
maintain them in a refolding competent state (e.g. so that they are amenable to refolding by ATP-dependent 
chaperones such as Hsp 70, when cellular conditions permit [90]), they can also interact with target proteins in a 
weak and transient manner, briefly stabilising them in order to facilitate their intrinsic ability to refold back to 
their native (functional) state. For example, αBc forms stable high-molecular-mass complexes with disordered, 
precipitation-bound intermediates of the target protein -lactalbumin that expose significant amounts of 
hydrophobicity to solution but also interacts through weak, transient interactions to suppress the aggregation of 
relatively stable -lactalbumin intermediates that expose less hydrophobicity to solution [36,91-94]. The weak 
transient interactions with target proteins is the mechanism that most likely predominates in cells that are not 
subjected to stress since these conditions are not conducive to large-scale protein destabilisation. Thus, it is 




































































(i.e. act as ‘holdases’) when binding is more energetically favourable than refolding. As such, their broad 
mechanism of action indicates that a more apt description of sHsp chaperones is as ‘stabilisers’ rather than 
‘holdases’. 
 
Currently, no well-defined target protein binding site(s) has been identified for mammalian sHsps. Various 
studies have suggested that target protein binding is mediated by the N-terminal domain [95-98] or the ACD 
[99-101]. Indeed, with regards to the latter, we [18] and others [17,20,102] have shown that isolated ACDs 
exhibit chaperone function. Moreover, binding may also be regulated by multiple regions of the protein. For 
example, it has been recently suggested that target protein access to a binding site formed between -sheets 4 
and 8 in Bc’s ACD is regulated by auto-inhibitory docking of the C-terminal I-X-I hinge region into this 
groove [22,101]. In this case, hydrophobic target proteins compete with this C-terminal region for binding at this 
site on Bc. The overall emerging picture is that there is no single target protein binding site on sHsps, rather 
binding is mediated by hydrophobic sites on the surface of the sHsp and these sites of interaction vary 
depending on the sHsp and target protein in question. 
 
The remarkable ability of sHsps to distinguish disordered protein intermediates from stable (native-like) 
intermediates is proposed to be based upon the intermediate’s free energy of unfolding [103], the lifetime of the 
intermediate and its relative degree of exposed hydrophobicity [91]. To-date, the most widely accepted model of 
sHsp chaperone action is that dissociated species (normally depicted as dimers) are the more chaperone-active 
species and large oligomers are ‘reservoirs’ of these species; the dissociated species associate with target 
proteins and then can re-associate with the large oligomers to form high-molecular-mass sHsp-target protein 
complexes. This model is favoured because (i) the dissociated species would expose more surface 
hydrophobicity to solution and therefore be more capable of binding to destabilised target proteins and, (ii) the 
chaperone activity of sHsps is dependent on subunit exchange. Recent work, including our own, has shed further 
light on the multi-faceted manner by which sHsps interact with aggregation-prone proteins, particularly those 
aggregating to form amyloid fibrils (reviewed in [30]). In summary, this work has demonstrated that sHsps can 
interact with monomeric, oligomeric, prefibrillar and fibrillar forms of target protein in order to prevent their 
aggregation, i.e. at each stage of the amyloid fibril-forming pathway. Based on this work we propose an 





































































Most studies that have tested the in vitro chaperone action of sHsps have involved addition of the chaperone 
prior to aggregation commencing. Thus, the design of such studies does not address the effect(s) sHsps have on 
the latter stages of aggregation, which is as important to consider since, in vivo, levels of sHsps in the cell 
increase after aggregation has commenced as a result of the activation of the stress response [104,105]. Apart 
from interacting with monomeric species, sHsps also bind to species formed further along the aggregation 
pathway, including mature amyloid fibrils [106-109]. For example, when introduced during the elongation 
phase of α-synuclein (α-syn) or amyloid- peptide (A aggregation, αBc prevents further fibril growth by 
binding along the length of mature fibrils, preventing secondary nucleation events that facilitate further fibril 
growth [106-108]. Our recent work, using apolipoprotein C-II (apoC-II) as a model fibril-forming protein, has 
shown that, by binding to fibrils, αBc stabilises them, preventing their (dilution-induced) fragmentation, and 
causes them to associate (tangle) into larger species reminiscent of protein inclusions [109]. Both fibril 
fragmentation and secondary nucleation can be the main sources of small oligomers thought to be responsible 
for the toxicity associated with the aggregation process [110]. Thus, the fibril-binding activity of sHsps helps to 
rationalise why sHsps (and indeed other Hsps) are found in protein deposits associated with disease, i.e. by 
binding to fibrils they facilitate their packing into inclusions, thereby limiting fibril fragmentation and secondary 
nucleation and providing an alternative protective mechanism to the cell. Recently αBc has also been shown to 
promote the dissociation of potentially toxic β2-microglobulin oligomers into monomers, highlighting another 
role these chaperones may have in cells to protect them from the adverse effects of protein aggregation [111].  
 
Despite our growing appreciation of the mechanisms by which sHsps interact with aggregating proteins there 
are still critical aspects of the chaperone model of sHsps that require further clarification: (1) There is no 
definitive evidence to-date that dissociated (dimeric) species are the sole chaperone active species (indeed for 
some sHsps such as Bc there is no direct evidence for the presence of dissociated species in solution) and some 
reports suggest that the large oligomers are also chaperone active [112]. For instance, some studies have 
indicated that there is no correlation between the concentration of sub-oligomeric species (or subunit exchange 
rate) and apparent chaperone activity [113]. Moreover, glutaraldehyde cross-linked α-crystallin, which is 
incapable of subunit exchange, retains significant chaperone activity in vitro [112]. (2) Little is known about the 
stoichiometry of mammalian sHsp-target protein complexes. To-date, efforts to study, in precise detail, the 
manner by which sHsps bind to target proteins to form complexes have been hampered by the large, 




































































heterogeneous samples. This problem is further confounded by the use of ‘bulk’ averaging techniques that can 
mask the presence of rare species formed in such dynamic systems. (3) The model is predominately based on in 
vitro studies of sHsp chaperone action; little is known about how this model relates to the chaperone activity of 
sHsps inside the crowded environment of the cell. For example, nothing is known about the precise 
concentrations of sHsps inside a cell (let alone cellular compartments such as the nucleus versus the cytoplasm) 
and since the oligomeric state of sHsps is concentration dependent (see discussion for Hsp27 below) it therefore 
remains to be elucidated which oligomeric forms are relevant in a cellular context.  
 
Defining the precise molecular mechanisms that underpin the chaperone activity of sHsps is essential for 
understanding their role in the suppression of aggregation in cells. Such knowledge will in turn inform efforts 
aimed at exploiting the biological activity of sHsps in the treatment of diseases.  
 
SECTION II: Role of post-translational modification in the structure/function of sHsps   
sHsps undergo extensive post-translational modification. In the lens, Acand Bc are subject to significant 
post-translational modification from early on in the organism’s lifespan [114]. The modifications include 
phosphorylation, truncation (particularly within the unstructured C-terminus), deamidation and glycation. In 
general, the mechanisms and functional roles of these alterations are unclear. 
 
Phosphorylation 
Both intra- and extra-lenticularly, the major post-translational sHsp modification is phosphorylation, the levels 
of which generally increase with age and under stress conditions [115-119]. For example, Bc is 
phosphorylated at three serine residues, Ser19, Ser45 and Ser59 [118,120,121]; phosphorylation at Ser45 is 
mediated by p44/p42 MAPK, at Ser59 by MAPKAPK-2 [118,122], whilst the kinase responsible for 
phosphorylation at Ser19 remains to be identified. Similarly, Hsp27 has three serine residues (Ser15, Ser78 and 
Ser82) that undergo phosphorylation [123,124]. Mitogen activated protein kinase activated protein (MAPKAP) 
kinase-2 is responsible for Hsp27 phosphorylation at all three sites [125,126]. In addition to Ac, Bc and 
Hsp27, phosphorylation is also common to other sHsps such as  Hsp20 [127,128] and occurs readily in all 
tissues. Phosphorylation of Hsp20 occurs at Ser16 and is mediated by cyclic nucleotide-dependent protein 




































































[130] and HSPB10 at Ser193 [131]), however the kinases responsible for these phosphorylation events in vivo 
remain to be definitively established.  
 
The introduction of a strong negative charge via phosphorylation at serine residues in the N-terminal region of 
αBc and Hsp27 alters their oligomerisation state. Phosphorylation reduces the average oligomer size, and 
increases oligomeric polydispersity and rate of subunit exchange of αBc [98,132-134], whereas it leads to a 
dramatic decrease in the size of Hsp27 oligomers, such that the triply phosphorylated isoform is predominately 
dimeric in solution [135,136]. Thus, under stress conditions, Hsp27 is phosphorylated, triggering dissociation of 
the high molecular mass Hsp27 oligomers [117,135,137,138] and an increase in the amount of exposed 
hydrophobicity on the newly formed Hsp27 dimers [139]. Phosphorylation also affects the cellular distribution 
of some sHsps. For example, following stress, phosphorylation of Bc and Hsp27 causes them to be 
translocated into the nucleus [140-144], presumably to protect nuclear proteins important to cell survival. Thus, 
phosphorylation of sHsps functions as a ‘molecular switch’ by regulating their structure and cellular localisation 
during periods of cellular stress. 
 
While purified αBc from bovine lens has been used to investigate of the effects of phosphorylation on αBc 
structure and function (as it is extensively phosphorylated with age [114,120,121,145,146]), such sources of 
sHsps do not afford homogeneous phosphorylated isoform. Instead these contain a mixture of non-
phosphorylated, mono-, di- and/or tri-phosphorylated forms in the one oligomer. Denaturation and subsequent 
ion-exchange high performance liquid chromatography can be used to separate these phosphorylated forms 
[147,148], however denaturation modifies the oligomeric state and activity of αBc once it is refolded [149]. As 
an alternative, phosphomimics are useful tools to investigate the effects of phosphorylation upon sHsp structure 
and function. Phosphomimics are created by replacing phosphorylatable serines with a negatively charged 
amino acid, such as aspartic acid or glutamic acid, to mimic the negative charge introduced by the addition of 
the phosphate group. The main advantage of phosphomimicking forms is that they afford a single homogeneous 
isoform of the protein. Significantly, phosphomimics of Bc and Hsp27 have similar attributes to the 
phosphorylated forms of the protein with regards to their oligomeric distribution, chaperone activity, subcellular 
localisation and cellular trafficking [136,143,150,151].  For example, the translocation of αBc to the nucleus and 
its association with nuclear speckles during mitosis is phosphorylation-dependent and this is replicated by the 




































































Hsp27 phosphomimic have comparable abilities to prevent the aggregation of target proteins in vitro [136]. Both 
S59 phosphorylated and S59E phosphomimicking forms of Bc bind to the anti-apoptotic regulator Bcl-2, 
promoting apoptosis of breast cancer MCF7 cells and therefore making them more susceptible to 
chemotherapeutic agents [152].  
 
The precise effect that phosphorylation has on the chaperone function of sHsps remains controversial. For 
example, some studies have concluded that Hsp27 phosphorylation increases chaperone activity (e.g. 
[136,138]), others have reported no difference (e.g. [153]) whilst others have reported that phosphorylation 
decreases activity (e.g. [135]). Similar discrepancies exist in the literature with regards to the effect of 
phosphorylation on Bc’s chaperone activity [133,134,148,150]. Various factors may account for these apparent 
differences including the target protein used to assess the chaperone activity, the final concentration of sHsp in 
the assays (wild-type Hsp27 dissociates at low concentrations and therefore may be predominately dimeric, like 
the phosphorylated form, in some assays [136,138]), and buffer and temperature conditions of the assay, all of 
which have been shown to influence sHsp chaperone activity [133]. Overall, the consensus emerging from work 
with Bc and Hsp27 concerning the impact of phosphorylation on sHsp chaperone function is that 
phosphorylation boosts chaperone activity by (i) promoting dissociation of large oligomers into smaller species 
[98,132,133,135,136] and (ii) enhancing their affinity to bind destabilised target proteins [103,138]. Based on 
structural modelling of a full-length Bc into a 24-mer oligomer [154]. Multiple molecular architectures of the 
eye lens chaperone B-crystallin elucidated by a triple hybrid approach), recent work has concluded that the 
negative charges introduced into the N-terminal domain of Bc by phosphorylation at S19, S45 and S59 result 
in oligomer destabilisation and dissociation due to the close proximity of adjacent N-terminal domains in the 
higher-order oligomeric structure [98]. Moreover, phosphorylation increases the rate of subunit exchange 
between oligomers and the flexibility of the N-terminal domain, leading to an increase in chaperone activity 
[98].  
 
With regards to the overall impact sHsp phosphorylation has a cellular context, it is envisaged that under normal 
conditions sHsps exists at relatively low levels in most cells and in non-phosphorylated forms. The activity of 
sHsps under these conditions is sufficient to maintain cellular proteostasis. Upon stress, the sHsps are rapidly 
phosphorylated, which modifies their oligomeric state and facilitates their translocation into the nucleus where 




































































chronic cell stress (e.g. that which occurs during some diseases) leads to an increase in sHsp levels in the cell 
(due to their up-regulation as part of the heat shock response pathway). This increase in expression facilitates 
the formation of a heterogeneous pool of sHsp oligomers (including phosphorylated and non-phosphorylated 
forms), which maximises the possible binding interactions of the sHsps with various intracellular target proteins. 
 
Other post-translational modifications 
In contrast to phosphorylation, other post-translational modifications, i.e. truncation (particularly from the C-
terminus), deamidation and glycation appear to be largely confined to the long-lived lens sHsps, Ac and Bc. 
Thus, they occur to a significant extent to these sHsps with age and are associated with aggregation of the 
crystallin proteins, and hence cataract formation. In vitro, it is well known that C-terminal truncation within the 
exposed C-terminal extension decreases the solubility of both Ac and Bc [6]. Deamidation occurs extensively 
to Ac and to Bc with age in the human lens [155] and leads to potential destabilising structural changes due 
to the introduction of an additional negative charge from the resultant aspartic or glutamic acid sidechains [156]. 
Glycation is a common post-translational modification of lens Ac and Bc and is particularly associated with 
diabetes where there are increased levels of blood glucose [157,158]. Glycation leads to the formation of 
covalent cross-links, aggregation and compromised chaperone activity of  c [159] with obvious implications 
for the development of diabetic cataract. 
 
SECTION III:  sHsps and their roles in disease  
In extra-lenticular tissues, the roles played by sHsps may vary according to specific cell and tissue types. Further 
complicating the picture in vivo is that the entire range of interactions of sHsps with target proteins that may 
occur in the crowded environment of the cell are not easily replicated by in vitro experiments [70]. Just as the 
precise mechanism(s) of action of sHsps in protein stabilisation remain to be elucidated in vivo, the precise roles 
of sHsps in the cellular pathologies of many diseases also remain largely unclear.  As a result of their increased 
expression under a variety of cellular stresses, particularly those present in pathological states (i.e. heat 
(inflammation), oxidation, ischaemia), it is perhaps not surprising that sHsps and their (mal)function has been 






































































Elucidating the precise role(s) played by sHsps in the context of disease is complex as they may be present as a 
consequence or cause of the disease. Moreover, as a result of their ubiquitous role in interacting with and 
stabilising a wide range of partially unfolded proteins against aggregation, sHsps are involved in many 
processes central to disease development and manifestation. These include cellular growth and differentiation 
[84,162,163]; interaction with cytoskeletal components such as actin and intermediate filaments [70,164,165]; 
and apoptosis [166]. Several of the sHsp family members (Hsp27, HSPB2, Hsp27, Hsp20 and Bc) have been 
attributed a protective role in the development of neurodegenerative and neuromuscular diseases, roles thought 
to be related to their abilities to both stabilise target proteins and to interact with cytoskeletal elements as the key 
features of these diseases are protein aggregation and defective axonal transport [70].  
 
The role of sHsps in neurodegenerative disease 
Bc is expressed at high levels in the neurons and glial cells of patients with neurodegenerative diseases such as 
Alzheimer’s (AD), Huntington’s, Alexander, Neuman-Pick, Creutzfeldt-Jakob (CJD) and amylotrophic lateral 
sclerosis (ALS) (summarised in [70]). Furthermore, Bc inhibits the aggregation of glial acidic fibrillary protein 
(GAFP) and -syn which are associated with Alexander and Parkinson’s disease (PD) pathologies, respectively 
[167,168]. Hsp20 and Hsp22 are also present at increased levels following neuronal stress associated with AD, 
PD, and ALS [169-173]. Hsp27 is also upregulated in AD and Neuman-Pick diseases [70]. Bc and/or Hsp27 
have also been identified in the protein deposits characteristic of several neurodegenerative and neuromuscular 
diseases (see below), co-depositing with the protein or peptide identified as being responsible for the 
pathological features of the disease [78]. 
 
The Rosenthal fibres characteristic of Alexander disease constitute abnormal inclusions containing Bc (some 
of which is ubiquitinated) [174], Hsp27 and GAFP [175,176]. The involvement of Hsp27 and Bc in the 
formation of Rosenthal fibres within astrocytes is  believed to be a response to an as-yet unknown stress caused 
by the disease [77]. The close association of sHsps with intermediate filaments in these pathologies [175] 
indicates that sHsps may play a role in their structural rearrangement [177]. Rosenthal fibres accumulate as a 
result of insufficient protein degradation in the cell. Bc’s lysine residues, particularly the three in the solvent-
exposed and highly flexible C-terminal extension (K166, K175 and K174) [9] serve as potential sites for the 
binding of ubiquitin in order to target the protein for degradation [178-180]. The presence of Bc-ubiquitin 




































































The pathology of AD is characterised by extracellular accumulation of amyloid plaques and intracellular 
neurofibrillary tangles [181]. Amyloid plaques are composed primarily of A peptides which are derived from 
the abnormal processing of -amyloid precursor protein by -secretase. In patients with familial AD, 
overproduction of A leads to early onset AD [182-185]. The level of Bc expression in brains of patients 
suffering AD is markedly increased compared to that in the normal human brain [105,186] presumably due to 
the cellular stress caused by disease. We and others have shown that aggregation of A and its associated 
cellular toxicity is prevented by Bc [187] or its isolated ACD [18] and thus sHsp overexpression in the context 
of AD may be as a protective mechanism. Fändrich et al. have shown that there is an intracellular component to 
the aggregation and pathogenic nature of A which may explain the presence of Bc in the extracellular plaques 
of AD [188]. The intracellular neurofibrillary tangles characteristic of AD (and other ‘tauopathies’) contains 
hyperphosphorylated tau protein [189]. Both Bc and Hsp27 are also found in these tangles, however, their 
contributions to the formation of these plaques and tangles, and hence the pathology of AD, remains unclear 
[190].   
 
The presence of Bc, Hsp27 and ubiquitin in CJD is thought to be related to the degenerative processes that 
neurons undergo as the disease manifests [179]. CJD is a transmissible spongiform encephalopathy resulting 
from the intracellular deposition of misfolded prion protein (PrPsc). The bovine precursor of this misfolded 
protein associates with Bc both in vitro and in vivo [191]. However, it remains unclear as to whether Bc acts 
to inhibit or enable the conversion of correctly folded prion to its toxic PrPsc form. Ubiquitinated Bc has also 
been identified by immunochemical analysis in cytoplasmic inclusions in brains of patients with multiple system 
atrophy [192]. More recently, it has been shown that the aggregation of SOD1, a major protein involved in the 
pathogenesis of ALS, is prevented by both Bc and Hsp27 [193,194] and that Hsp22, in concert with other 
chaperones, promotes autophagic removal of misfolded proteins in ALS [171]. 
 
PD is characterised by a gradual loss of dopaminergic neurons in the brain. The precise role of Bc in the 
development and progression of this disease is still unknown, despite the findings that the disease is 
characterised by ‘ballooned’ neurons [195] which express Bc [105]. Both PD and Huntington’s disease are 
intracellular protein aggregation diseases, like CJD. We have previously demonstrated that Bc prevents the 




































































to prevent their further growth [106,107,167]. Furthermore, several sHsps (Hsp20, Hsp22, HspB7 and HspB9) 
inhibit the aggregation of the polyQ huntingtin protein responsible for Huntington disease and also protect 
against cell death triggered by the deposition of the aberrant protein [173,196]. Our subsequent studies have 
shown, however, that polyQ aggregation occurs in stages, and while Bc potently inhibits the first stage of fibril 
formation by the polyQ protein, ataxin (responsible for spinocerebellar ataxia), through interaction with its 
Josephin domain, the second stage of polyQ aggregation can still proceed [197]. The potency of sHsps in 
individual disease states therefore appears to be very much dependent on target protein aggregation models and 
specific sequences can modulate this effect. 
 
The role of sHsps in multiple sclerosis 
Multiple Sclerosis (MS) is a relatively common demyelinating neurodegenerative disease. The exact mechanism 
of demyelination is unknown but appears to be an autoimmune disorder, triggered by environmental factors (e.g. 
viral infection). Patients with MS have numerous demyelinated plaques in the brain and spinal cord and these 
lesions have varying histopathological profiles depending on the stage of disease (i.e. acute or chronic). 
Inflammation plays a central role in disease progression as macrophages initially phagocytose the degraded 
myelin to form an acute plaque (with other immune cells such as T-lymphocytes and plasma cells) before a 
reactive gliosis is established, leading to chronic inflammation and plaque formation. It has been shown that 
Bc is the most prominent protein present in plaques of MS patients [198] and the CRYAB gene is the most 
highly induced in plaque tissue compared to normal tissue [199]. The increased expression of Bc, along with 
other Hsps, is proposed to be part of the oligodendrocyte’s survival response [180]. Initial studies identifying 
Bc bound to antibodies in the sera of affected patients suggested Bc as an auto-antigen to human T-cells in 
MS [173,200,201]. Subsequent studies showed that most of the sHsps (HspB1-8) were capable of binding 
immunoglobulin molecules with varying affinities and through multiple binding sites [201]. The association of 
these proteins with antibodies in the context of MS therefore appears to be related to their intrinsic ability to 
bind immunoglobulins rather than any inherent immunogenic property of the sHsp itself.  As proposed by Clark 
and Muchowski [160], the up-regulation of sHsps in diseases characterised by hyper- or autoimmune responses 






































































The role of sHsps in cancer 
Several sHsps, particularly Hsp27 and Bc, have been identified as playing potential roles in the pathogenesis 
of cancer.  Both Ac and Bc have been found in a range of tumours  [78] and especially in high-grade tumours 
[202]. Hsp27 has been identified at high levels in metastatic tissues compared to non-metastatic tissues, 
indicating a role in the metastasis of cancer [203,204]. Indeed, the ability to regulate apoptosis and thus prolong 
cell life, which in some cases is tumorigenic, is a feature consistent with the finding that Hsp27 and Bc 
expression is associated with increased cellular resistance to cytostatic agents [205]. Interestingly, the metastatic 
properties of breast cancer cells can be inhibited by phosphorylation of Bc. Phosphorylation at S59 specifically 
reduces the anti-apoptotic action of the protein, by affecting oligomer formation [204,206].  
 
In terms of the mechanisms by which sHsps promote tumorigenesis, many pathways have been identified by 
which sHsps regulate both the intrinsic and extrinsic pathways of apoptosis. For example, Chen et al.  showed 
that both Ac and Bc are able to bind to the pro-apoptotic Bcl-2 proteins Bax and Bcl-Xs, inhibiting their 
mitochondrial translocation and thereby switching off the intrinsic cell death pathway [202]. Specific naturally-
occurring mutations in the -crystallins (R116C Ac and R120G Bc) impair the ability of these sHsps to 
sequester Bax and Bcl-Xs  [207]. Previous work has also shown that Hsp27 interacts directly with Daxx to 
prevent Fas-mediated apoptosis [208], a cell death pathway that has previously been shown to involve Hsp27 
[209]. Future therapies may therefore include those which aim to suppress the action of sHsps in such situations 
[78]. For example, a recent clinical trial of an antisense oligonucleotide (ASO; OGX-427) designed to 
specifically inhibit the expression of Hsp27 for the treatment of prostate, bladder, breast and lung cancer has 
shown promising results [73]. 
 
The role of sHsps in cataract and myopathies 
Several naturally-occurring mutations in sHsps have been identified as being responsible for various forms of 
human cataract and myopathy. These will be discussed further in the following section describing the 






































































SECTION IV: Naturally-occurring mutations in sHsps – implications for altered function and disease 
Our understanding of the roles played by sHsps in disease aetiology has been increasingly enhanced by the 
identification of sHsp mutations directly associated with specific pathologies (Table 2). Typically, these 
mutations lead to altered chaperone function and therefore provide a clear link between molecular chaperone 
action and disease manifestation.  
 
Mutations in the -crystallin domain 
A naturally-occurring missense mutation (R120G) in the conserved ACD of Bc was first identified as being 
responsible for a form of desmin-related myopathy (DRM) [210]. R120G Bc is associated with aggregation of 
the intermediate filament protein, desmin, in the cytoplasm of myofibrils [211]. Desmin is essential for tensile 
strength in myofibrils of striated muscle and as a result DRM manifests with progressive muscle weakness. 
Moreover, gene mutations producing DRM are clinically heterogeneous with affected individuals often also 
exhibiting cardiomyopathy and cataract [210,212]. The formation of desmin aggregates was initially attributed 
to loss of chaperone function in Bc as a result of the R120G mutation, a hypothesis supported by the finding 
that formation of desmin aggregates could be delayed or prevented in vivo by the addition of wild-type Bc or 
other molecular chaperones [213]. Subsequent studies by our group and others have shown that the R120G 
mutation causes significant structural changes in Bc compared to the wild-type protein, leading to a loss of 
chaperone activity in vitro [214] and an inherent instability in the mutated protein [215]. Similarly, D140N Bc, 
a mutant identified in relation to congenital lamellar cataract, exhibits abnormal oligomerisation and impaired 
chaperone activity [216,217]. Recent biophysical studies by Hilton et al. [218] support the rationale that 
mutations in the ACD of Bc interfere with important transient interactions between subunits and therefore 
impact on the association and dissociation properties of the oligomeric form. The locations of naturally-
occurring, disease-associated mutations in a model of an Bc monomer is shown in Fig. 3. 
 
Mutation in Ac at the equivalent residue to R120G in Bc (i.e. R116C) results in hereditary cataract [219] and 
similar mutations in the gene coding for Ac have profound effects on lens opacity [220]. Mutation of R116 in 
the ACD of Ac causes a decrease in chaperone activity and subsequent aggregation of the natural target 
proteins of Ac in the lens (the - and -crystallins) [160]. Altered chaperone activity in R116C Ac (as with 




































































the mutation [221-223]. The substitution of an arginine for a cysteine at this position exposes a previously 
buried residue which most likely disrupts salt bridges and potentially leads to the formation of non-native, inter-
subunit disulphide bonds [224]. It is highly likely therefore that perturbation at this site is the reason for the 
abnormal oligomeric assembly of R116C Ac. This same residue is affected in the R116H mutant of Ac 
which also causes cataract [225]. As discussed in Section I, the interaction between A- and Bc is crucial to 
the maintenance of lens transparency. The R116C mutation in Ac also leads to a reduction in its protective 
ability against epithelial cell apoptosis in the lens [226]. A number of other site-specific mutations involving 
residues within the ACD have been found to be responsible for the development of either whole (lenticular) or 
nuclear cataract in humans (R49C and G98R Ac) [227], or in mice (R54C/Y118D Ac) [228]. 
 
Six naturally-occurring mutations in Hsp27 have been identified that are associated with Charcot-Marie-Tooth 
(CMT) disease, an inherited motor and sensory neuropathy, and distal hereditary motor neuropathy (HMN). 
Three of these mutations, R127W, S135F (one causing CMT and the other HMN) and R136W, are located in 
the ACD [229]. Neuronal cells transfected with the mutant Hsp27s are less viable than those expressing wild-
type Hsp27 and mutation also leads to altered neurofilament assembly within cells [229]. Similar mutations in 
the ACD of Hsp22, (i.e. K141E [230], K141T [231] and K141N [230,232,233]), also give rise to CMT disease 
indicating a critical role for sHsps in motor and sensory neurons.  
 
Mutations in the C-terminal region 
Outside of the ACD, naturally-occurring mutations in the C-terminal regions of both Ac and Bc are 
associated with disease. Mutation of conserved residues in Bc, R157H and G154S, lead to dilated 
cardiomyopathies but not cataract [234,235]. Another form of DRM arises from a deletion mutation (Q151X) in 
Bc [236]. Similarly, several other naturally-occurring mutations in the C-terminal region of Hsp27; P182L 
[229], P182S [237], R140G [238] and K141Q [239] cause distal HMN. Other rarer forms of fibrillar neuropathy 
have been identified, with deletions in the gene encoding Bc (CRYAB) resulting in the absence of the protein 
from affected muscle fibres [240]. A naturally-occurring deletion of a single nucleotide base in the CRYAB 
gene has been described and leads to a frameshift mutation in the C-terminal region of the resulting Bc protein 
[216]. Replacement of the wild-type sequence after residue 149 with 35 novel residues (450delA) results in 
posterior polar cataract [216]. Similarly, deletion of two bases in CRYAB leads to truncation at position 464 




































































importance of the C-terminal region in the functioning of sHsps. The complex phenotypical profiles associated 
with naturally-occurring mutations of Bc and Hsp27 are a consequence of their widespread tissue distributions 
(which largely overlap) and their wide array of cellular functions.  
 
Mutations in the N-terminal region 
In the N-terminal region, there are small regions of high (≥ 85%) sequence identity between members of the 
sHsp family. Thus, residues 48-55 in Bc contain the RFLDQxFG motif, which is also present in Hsp27 and 
Hsp20 [241]. Several naturally-occurring mutations in the N-terminal region of Hsp27 have been shown to exist 
in individuals affected by distal HMN (Table 2; [238]). 
 
The P20S mutant of Bc is the only cataract-causing mutation to be identified outside the ACD, but it affects a 
highly conserved N-terminal residue that also impairs the chaperone activity of Ac [242]. The naturally-
occurring mutation W9X in Ac has also been identified in individuals with cataract [243,244], as have 
mutations involving R21 (Table 1; [245-247]). Similarly, R49C [243] and R54H Ac [228] cause cataract, with 
R49C Ac exhibiting impaired chaperone function in vivo, resulting in greater perturbation of oligomer 
distribution and higher levels of cell death than even R116C Ac [243]. Furthermore, the same mutation 
induces apoptosis in human lens epithelial cells, an effect thought to be related to aberrant phosphorylation at 




From the above, it is apparent that there is still a great deal to learn about sHsps – they are very much an 
enigmatic class of molecular chaperone proteins. They appear to have many roles intra-cellularly that are based 
around their ability to stabilise proteins, thereby preventing their unfolding and potential aggregation under both 
normal (constitutive) and abnormal (stress) conditions in the cell. Their ability to interact with amyloid fibril-
forming proteins at the various stages of their aggregation pathway also imparts a multi-functional dimension to 






































































To rationalise sHsp functions will require a continued concerted effort on various fronts to: 
1. Understand fully the mechanism and role of sHsp subunit exchange (if any) in chaperone action. 
2. Understand the functional role of each of the three sHsp structural regions. 
3. Determine an accurate quaternary structure for B-crystallin and other sHsps (which, most likely, will 
provide major insight into points 1 and 2).  
4. Understand, and explain, the role of post-translational modification, particularly phosphorylation, in 
sHsp chaperone action. 
5. Understand why nature provided so many distinct sHsps – a feature indicating a need for diversity 
and/or compartmentalisation of sHsp functionalities. 
Clearly, insight into each of these areas will provide us with a much greater understanding of the links between 
sHsp function and disease, including the effect of sHsp mutations on disease manifestation and progression. 
Furthermore, these advances will lead to the potential targeting of specific sHsps in therapeutic treatments of the 
wide range of diseases associated with protein aggregation, many of which (e.g. AD, PD and cataract) will 
become much more prevalent in our increasingly ageing population.  
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Table 1 Tissue distribution of the major sHsps 
sHsp Alternative name Tissue distribution 
Ac HSPB4 Eye lens, spleen, thymus [248] 
Bc HSPB5 Eye lens, retina, heart, skeletal muscle, skin, brain, spinal cord, kidneys, lungs 
[37,57,58], cochlea [59], lacrimal gland duct & tears [61], sciatic nerve [70] 
Hsp27 HSPB1 Skeletal, cardiac and smooth muscle, brain and spinal cord (summarised in 
[70]) 
Hsp22 HSPB8 Muscle, brain, spinal cord (summarised in [70]) 
Hsp20 HSPB6 Skeletal, cardiac and smooth muscle , brain, spinal cord, sciatic nerve 
(summarised in [70]) 
 
Table 2  Disease-causing sHsp mutations in humans 
sHsp Mutant Disease 
Ac W9X, R12C, R12W, R21L, 
R49C, R54H, G98R, R116C*, 
R116H* 
Cataract [219,225,227,228,243,245-247,249] 
Bc R120G* Desmin-related myopathy, cataract [210] 
Bc P20S, R56W, D140N, 450delA Cataract [216,217,242,250] 
Bc R157H, G154S Dilated cardiomyopathy [234,235] 
Bc Q151X (STOP) Desmin-related myopathy [236] 
Bc 454delCT CRYAB gene Desmin-related myopathy [236] 
Bc 450delA CRYAB gene Cataract [216] 
Hsp27 R127W, S135F, R136W, T151L, 
P182L  
Distal hereditary motor neuropathy, motor and sensory 
neuropathy, Charcot-Marie-Tooth disease [229] 
Hsp27 P182S Distal hereditary motor neuropathy [237] 
Hsp22 K141N*, K141E* Distal hereditary motor neuropathy [230,232] 
Hsp22 K141N* Charcot-Marie-Tooth disease [233] 
Hsp22 K141T* Charcot-Marie-Tooth disease [231] 






































































Fig. 1A  
 
Fig. 1B  
 
















































































































































































































Fig. 1A Crystal structure of the Methanococcus jannaschii Hsp16.5 24-mer oligomer showing its large central cavity [13]. 
Reprinted with permission from [13]. 
 
Fig. 1B X-ray crystal structure of the ACD and C-terminal region of Bc without its flexible C-terminal extension [218]. At 
the top is shown the arrangement of the Bc dimer in which the six -strands of each ACD are arranged in an 
immunoglobulin-like fold. The intra-dimer contacts arise between -strands 6 and 7 of each subunit. The expanded section 
(below) shows in detail the inter-dimer interaction of an Bc peptide encompassing a palindromic nine amino acid sequence 
(residues 156 to 164), including the ‘IXI’ sequence (IPI in Bc; residues 159 to 161), with the fourth and eighth -strands of 
the adjacent Bc subunit. Reprinted with permission from [218]. 
 
Fig. 1C Model of the B-crystallin oligomer as determined from reconstruction of TEM images [27]. The porous nature of 
the oligomer is readily apparent along with the presence of a large central cavity. Reprinted with permission from [27]. 
 
Fig. 2 The chaperone mechanism of sHsps 
Multiple partially-folded protein intermediate states populate the folding/unfolding pathway of a protein. The mechanism by 
which sHsps, such as αB-c, prevent target protein aggregation (either amorphous or fibrillar) is dictated by the 
conformational stability and exposed hydrophobicity of the precursor protein intermediates. High affinity interactions occur 
with highly destabilised intermediates (which exceed the threshold of binding) and these are sequestered into stable high 
molecular mass complexes. Target proteins in these complexes can be re-folded through the action of other ATP-dependent 
chaperones or shuttled for degradation or via chaperone-mediated autophagy. Alternatively, weak, transient interactions 
occur with more stable protein intermediates, which re-direct them back to the folding pathway so as to facilitate their re-
folding. sHsps can also interact with pre-fibrillar and fibrillar aggregates formed by target proteins. By binding to these 
species sHsps stabilise them preventing their further elongation and fibril fragmentation and secondary nucleation events, 
which can be the main source of toxic oligomeric species formed during amyloid fibril-type aggregation. (Adapted from 
[95]). 
 
Fig. 3. Homology model of human B-crystallin monomer showing approximate locations of naturally-occurring disease 
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